非侵袭性SRT与老年肺癌患者手术一样好

据2010年芝加哥多学科研讨会在胸内肿瘤学介绍，据2010年芝加哥多学科研讨会介绍，新的研究表明，一种新型的靶向辐射治疗与早期肺癌患者的患者手术同样良好。该研讨会由美国辐射肿瘤学会（Astro），美国临床肿瘤学会（ASCO），国际肺癌（ISLAC）和芝加哥大学学会国际协会赞助。

在这项研究中，研究人员将早期进行了两次治疗方法肺癌老年患者:手术和立体定向放射治疗。几十年来，手术一直是标准的治疗方法，但一些肿瘤学家现在认为立体定向放射疗法可能同样有效，并正在世界各地进行试验研究。立体定向放射治疗，有时称为放射外科，是指一种或几种非常有针对性的放射治疗。立体定向辐射的品牌包括Axesse, CyberKnife, Gamma Knife, Novalis, Primatom, Synergy, X-Knife，TomoTherapy或三部曲。

在这项试验中，研究人员回顾了2005年至2007年在北荷兰治疗的早期肺癌老年患者。他们发现，接受任何一种治疗的患者在长期生存方面没有差异，但手术在头30天内的死亡风险更高。

“许多人会期望患者治疗放射疗法would do worse than those undergoing surgery," David Palma, M.D., lead author of the study and a Canadian radiation oncologist who performed the work while on a research fellowship at VU University Medical Center in Amsterdam, Netherlands, said. "At the time that these patients underwent treatment, patients only received radiation if they were too unwell for surgery or if they refused surgery. Because most radiotherapy patients had medical problems that prevented them from having surgery, we would expect them not to live as long as the surgery patients. Yet, despite this disadvantage, the radiotherapy patients lived just as long. This shows us that the stereotactic treatment is effective even in patients who have many medical problems. I would encourage patients with early lung cancer to talk to their oncologists to learn about all their treatment options, including radiation therapy."

---

---